A weekly overview of insider trading, highlighting significant purchases and sales by investors, directors, and executives. The transactions occurred between February 2, 2026, and February 6, 2026.
- Johnson & Johnson (JNJ) CEO Joaquin Duato sold 100,000 shares in the price range of $220.99 to $221.48 per share, for a total of $22.12M. Following the transaction, he continues to hold 307,807 shares.
- Johannes Oosthuizen, President of the U.S. Market at Merck (MRK), disposed of 15,000 shares at an average price of $121.87 per share, totaling $1.83M. His holdings stood at 21,197 shares after the sale.
- At Micron Technology (MU), EVP of Global Operations Manish Bhatia sold a total of 26,623 shares within the price range of $388.78 to $395.87 per share, resulting in proceeds of $10.41M. He continues to hold 323,486 shares.
- Goldman Sachs (GS) disclosed two insider sales in the week. CEO David Solomon let go of 272 shares at an average price of $938.92 per share for $255,387, retaining 16,171 shares. Meanwhile, Global Treasurer Carey Halio sold 2,846 shares in the price range of $921.25 to $932.81 per share for total proceeds of $2.64M, leaving her with 2,017 shares.
- Daniel Simkowitz, co-president at Morgan Stanley (MS), sold 32,968 shares at an average price of $182.61 per share, for a total worth of $6.02M. Following the transaction, his holdings stood at 359,137 shares.
- Intel (INTC) disclosed that EVP and CFO David Zinsner purchased 5,882 shares at an average price of $42.50 per share, for a total investment of $249,985. Following the purchase, he held 247,392 shares.
- Robert Ford, chairman and CEO of Abbott Laboratories (ABT), acquired 18,800 shares at an average price of $107.13 per share, amounting to $2.01M. His total holdings increased to 469,508 shares.
- GameStop (GME) Director Lawrence Cheng bought 5,000 shares at an average price of $22.87 per share, representing a total purchase value of $114,368. He now holds 88,000 shares.
- International Business Machines (IBM) reported that Director David Farr purchased 1,000 shares at an average price of $304 per share, for a total investment of $304,000. Following the transaction, he owned 9,258 shares.
- Naimish Patel, Chief Medical Officer at CRISPR Therapeutics (CRSP), acquired 1,508 shares at an average price of $32.96 per share, totaling $49,704. He held 1,508 shares after the purchase.